Northwest Biotherapeutics, a biotech company focused on the development of immunotherapy products for the treatment of cancers, today announced its partnership with King’s Health Partners, in which the companies will manufacture and deliver a new treatment for patients with brain cancer as part of its ongoing 240-patient clinical trial for Glioblastoma multiforme (GBM), the most fatal form of brain cancer.
Per the arrangement, specialists at King’s College London will manufacture Northwest’s immune therapy treatment, DCVax®, for the clinical trial, which will take place at King’s College Hospital NHS Foundation Trust in London.
Among several anticipated benefits, the collaboration generates additional manufacturing capacity and flexibility for DCVax without requiring capital investment by Northwest.
“We are excited about partnering with such prestigious institutions as King’s College London and King’s College Hospital,” Linda Powers, CEO of Northwest stated in the press release. “This partnership can help accelerate our brain cancer clinical trials, and also help extend lives through compassionate use treatments for other patients while the trials are ongoing. This partnership also expands our manufacturing capacity and flexibility in a highly cost effective way – a great arrangement both for patients and for our programs.”
The collaboration enables King’s College Hospital to join Northwest’s ongoing clinical trial for GBM brain cancer, which is currently taking place at more than 30 clinical trial sites across the U.S. Northwest reports that the partnership also allows for the treatment of patients on a compassionate use basis, specifically for those who do not fully meet the criteria to enroll on the clinical trial, but may benefit from the treatment.
“We are pleased to be leading the way in bringing these novel immune therapies to patients in the UK,” stated Dr. Ashkan Keyoumars, a specialist, neurosurgeon, associate professor in Neurosurgery, and lead for King’s College Hospital’s neuro-oncology department. “Brain cancers are some of the most lethal cancers, and there is a great need for new and better treatments. The positive data from the phase I clinical trials in the U.S. were very encouraging in delaying disease progression and extending survival times, without significant toxic side effects. We are hopeful that similar results will be seen in the large, randomized clinical trial which we are now helping to bring to the UK.”
For more information visit www.nwbio.com or www.kingshealthpartners.org
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment